FDA Grants Approval for Dostarlimab in Advanced Rectal Cancer Treatment

The U.S. FDA has approved dostarlimab (Jemperli, GSK) for adults with stage 2 and 3 MSI-H/dMMR locally advanced rectal cancer. This decision follows positive results from the AZUR-1 trial, where 68% of patients achieved a clinically complete response at 12 months with monotherapy. This approval offers a new treatment option for a specific subset of rectal cancer patients.